Spots Global Cancer Trial Database for monalizumab
Every month we try and update this database with for monalizumab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer | NCT05903092 | Small Cell Lung... SCLC Extensive Stage... | Durvalumab Monalizumab Carboplatin or ... Etoposide | 18 Years - | Hoosier Cancer Research Network | |
| A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer | NCT05221840 | Non-Small Cell ... | Durvalumab Oleclumab Monalizumab Placebo | 18 Years - | AstraZeneca | |
| Monalizumab and Trastuzumab In Metastatic HER2-pOSitive breAst Cancer: MIMOSA-trial | NCT04307329 | Breast Cancer | Monalizumab Trastuzumab | 18 Years - | The Netherlands Cancer Institute | |
| Monalizumab and Trastuzumab In Metastatic HER2-pOSitive breAst Cancer: MIMOSA-trial | NCT04307329 | Breast Cancer | Monalizumab Trastuzumab | 18 Years - | The Netherlands Cancer Institute | |
| Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | NCT02643550 | Head and Neck N... | Monalizumab Cetuximab Anti-PD(L)1 | 18 Years - | Innate Pharma | |
| Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), The ARCHON-1 Trial | NCT03801902 | Locally Advance... Locally Recurre... Stage II Lung C... Stage III Lung ... Unresectable Lu... | Accelerated Hyp... Biospecimen Col... Computed Tomogr... Durvalumab Magnetic Resona... Monalizumab Oleclumab Radiation Thera... | 18 Years - | National Cancer Institute (NCI) | |
| Monalizumab and Trastuzumab In Metastatic HER2-pOSitive breAst Cancer: MIMOSA-trial | NCT04307329 | Breast Cancer | Monalizumab Trastuzumab | 18 Years - | The Netherlands Cancer Institute | |
| Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer | NCT04590963 | Squamous Cell C... | Monalizumab Cetuximab Placebo | 18 Years - 130 Years | AstraZeneca | |
| Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer | NCT03794544 | Resectable Early-stage NSCLC | Durvalumab Oleclumab Monalizumab Danvatirsen | 18 Years - 102 Years | MedImmune LLC | |
| Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | NCT02643550 | Head and Neck N... | Monalizumab Cetuximab Anti-PD(L)1 | 18 Years - | Innate Pharma | |
| Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer | NCT03794544 | Resectable Early-stage NSCLC | Durvalumab Oleclumab Monalizumab Danvatirsen | 18 Years - 102 Years | MedImmune LLC | |
| A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer | NCT05221840 | Non-Small Cell ... | Durvalumab Oleclumab Monalizumab Placebo | 18 Years - | AstraZeneca | |
| Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer | NCT04590963 | Squamous Cell C... | Monalizumab Cetuximab Placebo | 18 Years - 130 Years | AstraZeneca | |
| Study of a Humanized Antibody Initiated 2 Months After an HLA Matched Allogenic Stem Cell Transplantation | NCT02921685 | Hematologic Mal... | Monalizumab | 18 Years - 70 Years | Institut Paoli-Calmettes |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
